Skip to content

Efficacy of Pregabaline on Trigeminal Neuralgia

Compare of The efficacy of Pregabaline and Carbamazepine on patients with Trigeminal Neuralgia

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20161103030680N7
Enrollment
20
Registered
2018-01-28
Start date
2015-12-22
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Trigeminal Neuralgia. Trigeminal neuralgia

Interventions

Intervention 1: First group: Ten patients who assigned randomly in this group take Pregabaline seventy-five milligrams two times daily for thirty days. After five days interval without any drug these
Treatment - Drugs
First group: Ten patients who assigned randomly in this group take Pregabaline seventy-five milligrams two times daily for thirty days. After five days interval without any drug these patients take Ca
First group: Ten patients who assigned randomly in this group take Carbamazepine two hundred milligrams two times daily for thirty days. After five days interval without any drug these patients take P

Sponsors

Shahed University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Age between eighteen to seventy-five years old. Suffering from Idiopathic Trigeminal neuralgia according to International Headache Society criteria.

Exclusion criteria

Exclusion criteria: Suffering from other kinds of head and facial pain History of psychiatric diseases, Renal failure, liver failure, Heart failure, Thrombocytopenia, Leuckopenia, Anemia and malignancy Pregnancy and Breast feeding

Design outcomes

Primary

MeasureTime frame
Neuralgic pain intensity. Timepoint: Before starting the drugs and from days twenty- eight to thirtieth in each period. Method of measurement: Visual Analogue scale (VAS).;Neuralgic pain intensity. Timepoint: Before starting the drugs and from days twenty- eight to thirtieth in each period. Method of measurement: 5 points verbal rating scale.;Duration of neuralgic pain. Timepoint: Before starting the drugs and from days twenty- eight to thirtieth in each period. Method of measurement: Average duration of attacks in seconds.;Frequency of neuralgic pain. Timepoint: Before starting the drugs and from days twenty- eight to thirtieth in each period. Method of measurement: Number of attacks in one day.

Secondary

MeasureTime frame
Unpredictable drug reactions (Pruritus, Burning sensation, Skin redness). Timepoint: immediately after patient alarm. Method of measurement: Observation, Examination, and refer to the specialist.;Drowsiness. Timepoint: Immediately after patient alarm. Method of measurement: Observation, examination, and refer to the specialist.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSiamak Afshinmajd

Shahed University

safshinmajd@gmail.com+98 21 5121 5080

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026